Century Therapeutics, Inc.IPSCEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics. Bristol Myers Squibb acquired the company in January 2024.
IPSC Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-20.7M
Net Profit
$-19.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.25
Century Therapeutics, Inc. Q4 FY2025 Financial Summary
Century Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-19.2M (up 46.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-19.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Century Therapeutics, Inc. Annual Revenue by Year
Century Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $109.2M).
Century Therapeutics, Inc. Quarterly Revenue & Net Profit History
Century Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-19.2M | N/A |
| Q3 FY2025 | $0 | — | $-34.4M | N/A |
| Q2 FY2025 | $0 | — | $-32.5M | N/A |
| Q1 FY2025 | $109.2M | +12667.7% | $76.6M | 70.1% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $109.2M | $0 | $0 | $0 |
| YoY Growth | 12667.7% | N/A | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $315.6M | $284.7M | $244.7M | $223.7M |
| Liabilities | $75.2M | $74.8M | $68.4M | $64.8M |
| Equity | $240.4M | $209.9M | $176.3M | $158.9M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-34.6M | $-27.6M | $-25.6M | $-16.1M |